Editor's note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Armed with a pair of phase 3 trial readouts, the two companies are planning to file for approval of their first-in-class candidate ... current drugs like allopurinol and febuxostat aren’t ...